No data to show
XOSL
ZLNA
Market cap6mUSD
Mar 04, Last price
2.05NOK
1D
-5.96%
1Q
-3.76%
IPO
-93.54%
Name
Ultimovacs ASA
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.51%
Rev. gr., 5y
%
Revenues
0k
Net income
-189m
L+28.82%
CFO
-163m
L-13.92%
Earnings
May 05, 2025
Profile
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Valuation
Title NOK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 126,602 | 107,069 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (126,602) | (107,069) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (20,891) | |||||||||
Tax Rate | ||||||||||
NOPAT | (126,602) | (86,178) | ||||||||
Net income | (189,239) 28.82% | (146,901) -11.91% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 300 | 5,484 | ||||||||
BB yield | -0.01% | -0.15% | ||||||||
| Debt | ||||||||||
Debt current | 1,864 | 1,827 | 1,767 | |||||||
Long-term debt | 2,324 | 5,599 | 9,193 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,482 | |||||||||
Net debt | (103,183) | (259,133) | (414,349) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (163,404) | (189,827) | (167,695) | |||||||
CAPEX | (17) | (25) | (195) | |||||||
Cash from investing activities | 8,529 | 14,034 | 8,691 | |||||||
Cash from financing activities | (2,215) | (1,847) | 3,577 | |||||||
FCF | 1,659 | (124,613) | (89,680) | |||||||
| Balance | ||||||||||
Cash | 107,371 | 266,559 | 425,309 | |||||||
Long term investments | ||||||||||
Excess cash | 107,371 | 266,559 | 425,309 | |||||||
Stockholders' equity | (1,058,972) | (797,216) | (626,957) | |||||||
Invested Capital | 1,145,217 | 1,080,320 | 1,081,788 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 34,398 | 34,247 | ||||||||
Price | 2.33 -98.10% | 122.80 11.64% | 110.00 -2.48% | |||||||
Market cap | 4,224,074 12.13% | 3,767,170 3.16% | ||||||||
EV | 3,964,941 | 3,352,821 | ||||||||
EBITDA | 2,769 | (123,834) | (104,421) | |||||||
EV/EBITDA | ||||||||||
Interest | 382 | 15,839 | ||||||||
Interest/NOPBT | ||||||||||